Sanofi ’ s biologic ‘ Dupixent ’ to treat atopic dermatitis gets approval in India
Sanofi Healthcare India has announced that it has received marketing authorization for Dupixent ® ( dupilumab ), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable . Dupixent ® can be used along with or without topical therapy . Globally , Dupixent ® has transformed the treatment landscape for patients around the world by targeting the type 2 inflammation that underlies the disease , rather than broadly suppressing the immune system .
With more than 600,000 patients being treated with Dupixent ® globally , Dupixent ® will soon be available as an option for controlling moderate to severe atopic dermatitis for adults in India . Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement .
Inflation law drives biologic drugs to outpace small molecules in venture financing in US , finds GlobalData
BioTech
Biotechs located in the US received 19 % or $ 7.6 billion more venture financing from 2018-2023 ( YTD ) for biologic innovator drugs compared to small molecule innovator drugs , driven by the enactment of the inflation law in the country to drive down prescription drug prices , reveals GlobalData , a leading data and analytics company .
According to GlobalData ’ s Pharma Intelligence Center Deals database , the US biotechs saw 48 % or $ 1.1 billion more in innovator drug venture financing , reaching a total deal value of $ 3.2 billion in 2023 over innovator small molecules . Overall , venturing financing for biologic drugs reached a total deal value of $ 48.9 billion between 2018-2023 ( YTD ).
BIOVOICENEWS . COM 09